ESC Premium Access

Use of Non-vitamin K antagonist Oral Anticoagulants in a real-world setting: a community pharmacy-based study.

Congress Presentation

About the speaker

Mr Andreas Capiau

Ghent University, Ghent (Belgium)
0 follower

7 more presentations in this session

Potential real-world benefits of low-dose rivaroxaban in Chinese stable cardiovascular patients

Speaker: Associate Professor B. Yan (Hong Kong, CN)


Prediction of major bleeding in patients receiving DOACs for venous thromboembolism: a prospective cohort study.

Speaker: Doctor M. Vedovati (Perugia, IT)


Risk of arterial calcification by conventional vitamin K antagonist treatment

Speaker: Doctor S. Hasific (Odense, DK)


Efficacy and safety of uninterrupted periprocedural edoxaban in patients undergoing catheter ablation for atrial fibrillation: Prospective KYU-RABLE study

Speaker: Professor N. Takahashi (Oita, JP)


Real world persistence with direct oral anticoagulants in anticoagulation naive patients with atrial fibrillation

Speaker: Doctor G. Denas (Padua, IT)


Access the full session

Perspectives on anticoagulation across cardiovascular disease

Speakers: Mr A. Capiau, Associate Professor B. Yan, Doctor M. Vedovati, Doctor S. Hasific, Professor N. Takahashi...

About the event


ESC Congress 2019

31 August - 4 September 2019

Sessions Presentations

Related content

ESC Premium Access

RIPCORD 2 - Panel discussion.

29 August 2021

ESC Premium Access

RIPCORD 2 - Discussant review.

29 August 2021

ESC Premium Access

Recommendations from the Commission - 6-10.

29 August 2021

ESC 365 is supported by

logo Novo Nordisk